Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
DRTS moved a median of -0.01% 30 minutes after news, and 0.00% by the close. How DRTS actually reacts to news — the realized, point-in-time move the market made, measured across 211 labeled events over the last three years with zero look-ahead.
DRTS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 188 |
| 30-min | -0.01% | 40% | 196 |
| 60-min | -0.01% | 39% | 207 |
| to close | 0.00% | 49% | 207 |
| Middle 50% of DRTS reactions | -1.37% to +1.85% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 211 |
Half of all Alpha Tau Medical Ltd. - Ordinary Shares news events land between -1.37% and +1.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DRTS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DRTS's baseline. Nothing else.
Recent DRTS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alpha Tau to Participate in October Investor Conferences | Press release | GlobeNewswire | -0.79% | +0.53% | |
| Alpha Tau to Participate in September Investor Conferences | Press release | GlobeNewswire | +1.40% | +2.65% | |
| Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions | Press release | GlobeNewswire | +0.99% | -3.95% | |
| Form 6-K Alpha Tau Medical Ltd. For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | +0.99% | -3.95% | |
| Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) | Press release | GlobeNewswire | +0.84% | — | |
| Form 6-K Alpha Tau Medical Ltd. For: Aug 10 | SEC filing · Form 6-K | SEC EDGAR | +0.84% | — | |
| Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specif | Press release | GlobeNewswire | -6.55% | -2.99% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | -6.55% | -2.99% | |
| Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center | Press release | GlobeNewswire | +1.65% | +0.40% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +1.65% | +0.40% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | +2.15% | +1.49% | |
| Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel | Press release | GlobeNewswire | +5.88% | +3.48% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jun 23 | SEC filing · Form 6-K | SEC EDGAR | -0.74% | -0.49% | |
| Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control | Press release | GlobeNewswire | +1.89% | +1.68% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | +1.89% | +1.68% | |
| Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients | Press release | GlobeNewswire | +5.75% | +14.75% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | +5.75% | +14.75% | |
| Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -6.24% | -11.25% | |
| Form 6-K Alpha Tau Medical Ltd. For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | -6.24% | -11.25% | |
| Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.03% | +4.40% | |
| Alpha Tau to Participate in May Investor Conferences | Press release | GlobeNewswire | +0.38% | -5.82% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 18 | SEC filing · Form 6-K | SEC EDGAR | -3.03% | +4.40% | |
| Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET | Press release | GlobeNewswire | -3.69% | +6.05% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 11 | SEC filing · Form 6-K | SEC EDGAR | -3.69% | +6.05% | |
| Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma | Press release | GlobeNewswire | +0.51% | +8.82% | |
| Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma | Press release | GlobeNewswire | +0.51% | +8.82% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 08 | SEC filing · Form 6-K | SEC EDGAR | +0.51% | +8.82% | |
| Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute | Press release | GlobeNewswire | -0.65% | +1.29% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 07 | SEC filing · Form 6-K | SEC EDGAR | -0.65% | +1.29% | |
| Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab | Press release | GlobeNewswire | -4.12% | -4.77% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 05 | SEC filing · Form 6-K | SEC EDGAR | -4.12% | -4.77% | |
| Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 | Press release | GlobeNewswire | -3.46% | -15.87% | |
| Form 6-K Alpha Tau Medical Ltd. For: May 04 | SEC filing · Form 6-K | SEC EDGAR | -3.46% | -15.87% | |
| Form EFFECT Alpha Tau Medical Ltd. | SEC filing · Form EFFECT | SEC EDGAR | -3.46% | -15.87% | |
| Form F-3 Alpha Tau Medical Ltd. | SEC filing · Form F-3 | SEC EDGAR | -1.28% | -6.53% | |
| Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies | Press release | GlobeNewswire | -1.71% | -3.65% | |
| Form 6-K Alpha Tau Medical Ltd. For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | -1.71% | -3.65% | |
| Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) | Press release | GlobeNewswire | -1.48% | -1.84% | |
| Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial | Press release | GlobeNewswire | -1.48% | -1.84% | |
| Form 6-K Alpha Tau Medical Ltd. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | -1.48% | -1.84% | |
| Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 | Press release | GlobeNewswire | +1.61% | +5.52% | |
| Form 6-K Alpha Tau Medical Ltd. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +1.61% | +5.52% | |
| Alpha Tau to Present at Sidoti March Virtual Small Cap Conference | Press release | GlobeNewswire | +0.55% | -0.41% | |
| Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.75% | +2.70% | |
| Form 20-F Alpha Tau Medical Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.75% | +2.70% | |
| Form 6-K Alpha Tau Medical Ltd. For: Mar 09 | SEC filing · Form 6-K | SEC EDGAR | -0.75% | +2.70% | |
| Form S-8 Alpha Tau Medical Ltd. | SEC filing · Form S-8 | SEC EDGAR | -0.75% | +2.70% | |
| Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer | Press release | GlobeNewswire | +0.13% | -1.14% | |
| Form 6-K Alpha Tau Medical Ltd. For: Feb 24 | SEC filing · Form 6-K | SEC EDGAR | +0.13% | -1.14% | |
| Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead | Press release | GlobeNewswire | -1.80% | -6.82% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DRTS section they belong to.
Where else DRTS is measured.
DRTS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alpha Tau Medical Ltd. - Ordinary Shares's median reaction calculated?
Every labeled DRTS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 211 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of DRTS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DRTS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.